The continuous rain in the rainy season did not extinguish the enthusiasm of biopharmologists to participate in the CBA conference. At the end of June, we gathered in Suzhou and had an in-depth and fruitful exchange on the current situation, the way out and the future development trend of biomedicine at the Suzhou International Expo Center on the shore of the beautiful Jinji Lake. Everyone gathered together to rekindle confidence in the future development with the enthusiasm of biomedical people.
Based on innovation! Shanghai Ji Cheng Wei attracts attention!
Shanghai Jizhiwei Biotechnology Co., Ltd. was invited to participate in this event. Dr. Marième NDJIM, Director of Business Development and Scientific Consulting at genOway in France, delivered a wonderful report entitled "Improving the Predictability of Preclinical Models for the Development of Safer Drugs" at the [Macromolecule Field] venue.
Report to the scene
Preclinical animal models play a key role in the evaluation of drug efficacy and safety, and accurate preclinical trial evaluation can help improve the success rate and clinical translation rate of drug clinical trials.
After a brief introduction to the French company genOway, Dr. Marième NDJIM focused on the characteristics of a variety of preclinical animal models and the application data validated in cooperation with a number of well-known pharmaceutical companies. Through cutting-edge gene editing technology, genOway humanizes the targets of the drug, including T cell-related targets and other immunotherapy targets, which can better serve the efficacy evaluation stage of preclinical target drug development. In addition, genOway has constructed a severe immunodeficiency model on the background of BALB/c mice, on which the human immune system can be reconstructed by injection of human hematopoietic stem cells, and the reconstructed model can be widely used in a variety of research fields. Dr. NDJIM presented data on tumor model construction and some of the published research results. genOway has also developed animal models for pharmacokinetic/pharmacodynamic (PK/PD) studies that can be adapted to a wider range of customer needs.
At the end of the presentation, Dr. NDJIM introduced genOway's joint venture in China, Shanghai Jizhiwei Biotechnology Co., Ltd. At present, Shanghai Gene has achieved local production, and can provide a variety of preclinical animal models to meet the needs of customers in China and the Asia-Pacific region.
Through these innovative collaborations, the company and its French team provide strong support for global pharmaceutical research and development, helping every step of new drug development.
Exchange and learn, keep the wonderful moments!
In this conference, Shanghai Jizhiwei set up a booth at D160-162 in Hall D3, which attracted the attention of many participating scholars. The experts and scholars showed strong interest in the strain models of the company, and actively consulted the characteristics of each model and its use in different application scenarios.
All experts gathered at the cocktail party to go to the bright appointment!
Shanghai Gene & Co. sponsored the evening's cocktail party, and the special band brought a unique live performance. The guests were completely relaxed in a relaxed and pleasant atmosphere, communicating and sharing with each other, and talking about future development. This event not only provides a communication platform for pharmaceutical innovation and development, but also creates unlimited possibilities and cooperation opportunities for enterprises to enter the international market.
Wonderful moments at the cocktail party
China is in the historic process of moving from a pharmaceutical country to a pharmaceutical power, and it requires the efforts and support of every biopharmaceutical person to gather innovative ideas and consensus, break down barriers to innovation elements, and promote the high-quality development of the industry. We hope to bring more choices and opportunities to all colleagues in the industry to move forward together. It is expected that China's biopharmaceutical industry, which is forging ahead, can show its outstanding style on a broader international stage.
If there is any infringement of the above pictures and videos, please contact us to delete.
END
Provided by Shanghai Giving
About us
genOway, a world-renowned animal model supplier, was founded in France in 1999, based on the original research of models, and has an exclusive license for CRISPR/Cas9 basic patent portfolio (Sigma-Aldrich, Berkeley, Broad), and has achieved remarkable results in the research and development of transgenic mice, rats and cell models, and has established cooperation with 17 of the world's top 20 pharmaceutical companies and more than 380 academic institutions.
In 2023, a Sino-French joint venture company was established in China, Shanghai Jizhiwei Biotechnology Co., Ltd., which has established complete localized production facilities and simultaneously built another global R&D platform in addition to Europe and the United States, which will greatly shorten the supply cycle in China and other Asia-Pacific regions, ensure that customers can obtain the required models and application solutions in a timely manner, and jointly promote innovation and development in the field of medical research.